Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 20/20 | 1.00 |
| ▸ | PDE4A | P27815 | 15/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 15/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6590136 | 0.87 | PDE4D (0.98) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6592499 | 0.87 | PDE4D (0.77) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6585981 | 0.83 | PDE4D (0.70) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6592230 | 0.80 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6592235 | 0.80 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6586660 | 0.80 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7450274 | 0.76 | PDE4D (0.66) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6588161 | 0.76 | PDE4A (0.71) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8344691 | 0.76 | PDE4A (0.71) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6586232 | 0.75 | PDE4D (0.62) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589951-B1 | N right-arrowO derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF pharmaceutically acceptable salt thereof are PDE 4 and TNF alpha inhibitors. | ZAMBON GROUP S.P.A. (IT) | 2003-07-08 | — | — | US | claimed |
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | ZAMBON GROUP S.P.A | 2004-03-04 | — | — | US | disclosed |
| EP-1042300-B1 | PHTHALAZINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-02-11 | — | — | EP | disclosed |
| US-6589951-B1 | N right-arrowO derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF pharmaceutically acceptable salt thereof are PDE 4 and TNF alpha inhibitors. | ZAMBON GROUP S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | PDE5A, PDE3B, PDE3A | PDE4D 22/4885PDE4A 7/4885PDE4B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.